Résumé
We evalueted the efficacy of oral levofloxacin (500mg/day for 7-21 days) in the treatment of adults patients with community-acquired pneumonia (CAP) requiring hospitalization in an open prospective stydy. The microbiological cause of the pneumonia was identified in 14/20 patients using lower respiractory tract secretions obtained by bronhoscopy (12) and/or blood culture (2). Eight patients has S.pneumoniae, 2 P.aeruginosa, 1 H.influenzae, 1 S.aureus, 1 mixed S.aureus and K.pneumoniae, and 1 E.coli and Grp.D Streptococcus. All of the patients evaluated were judged to be improved or cured. Levofloxacin is an additional option as monotherapy for the treatment of CAP.
Sujets)
Humains , Adulte , Mâle , Femelle , Adulte d'âge moyen , Infections bactériennes à Gram négatif/traitement médicamenteux , Infections bactériennes à Gram positif/traitement médicamenteux , Infections communautaires/étiologie , Ofloxacine/pharmacocinétique , Ofloxacine/usage thérapeutique , Pseudomonas aeruginosa/isolement et purification , Streptococcus pneumoniae/isolement et purification , Loi du khi-deux , Bâtonnets et coques aérobies à Gram négatif , Pneumopathie infectieuse/diagnostic , Pneumopathie infectieuse/traitement médicamenteux , Études prospectivesRésumé
Este artigo é resultado de revisäo de literatura, acrescido da experiência dos autores, no tratamento antimicrobiano da endocardite infecciosa, tendo como objetivo principal o de orientar a atualizar aqueles que tratam dessa afecçäo. Também säo comentados alguns aspectos referentes a bacteriologia e a perspectivas com relaçäo ao uso de novos agentes, no tratamento dessa doença